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A BST R AC T   
 
Aim: To investigate the accuracy of multiparametric prostate magnetic resonance imaging (mpMRI) 
in determining the diagnosis and treatment options of prostate cancer (PCa), and its pathology 
correlation.  
Methods: Between October 2017 and January 2018, 73 patients were subjected to an mpMRI at our 
clinic. Of these patients, 11 were radical prostatectomy (RP) after treatment, and four were post- 
radiation therapy (RT) follow-up. The remaining 58 patients were assigned to the PSA elevation and 
/ or positive digital rectal examination (DRE) patient group in this study and their outcomes were 
evaluated. 
Results: Of the 58 patients included in the study, 13 were found to have a PI-RADS 5 on mpMRI 
and in 9 (90%) of 10 patients undergoing simultaneous biopsy, PCa was detected. The biopsy results 
of all cases evaluated as PI-RADS 1 were benign. All of the patients who were ISUP 3 and above had 
a PI-RADS 5. Patients with a PI-RADS score of 4 and above being ISUP 2 and above was statistically 
significant (p=0.011). A case had undergone a previous radical prostatectomy assessment revealed 
that tPSA increased to 2 ng/ml during the follow-up, and so RT was added to the treatment; although 
LAP was identified in the left iliac region on an mpMRI performed upon the continued increase of 
tPSA. During the follow-ups of the patient who had regional RT, the tPSA dropped below 0.01 ng/ml.  
Conclusion: The results of our study show that mpMRI can gain a new and important place in urology 
due to the guidance it provides in biopsies, facilitating targeted biopsy, its effectiveness in determining 
treatment modalities and its importance in post-PCa treatment follow-ups. 
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Introduction 
Prostate cancer (PCa) is the second most 
common cancer among men in the United 
States of America (USA) and the second-
leading cause of cancer-related deaths [1, 2]. 
The leading risk factor for prostate cancer is 
age, with the average age of diagnosis of PCa 
being 66 [3].  
Although prostate cancer is common, the 
mortality risk is low. At this point, a risk 
classification has been made in order to answer 
the “Which PCa is fatal?” question. The 
National Comprehensive Cancer Network 
(NCCN) guidelines identifies six different risk 
groups, being very low, low, intermediate, high, 
very high and metastatic. This classification is 
based on “whether the cancer is limited to the 
prostate, the Gleason score, the number of 
specimens with cancer, the prostate-specific 
antigen (PSA) value, PSA density (PSAd) and 
the presence of metastasis to lymph nodes or 
other organs” [4, 5]. 
PSA and digital rectal examinations (DRE) are 
the current screening methods, with a biopsy 
recommended in cases where PSA≥4ng/ml or a 
suspicious exam finding is present. The 
systematic biopsy of the prostate involves the 
use of a thick needle to take specimens of the 
peripheral zone, in line with certain standards. 
At this point, two basic issues need to be taken 
into account, the first of which is the failure to 
diagnose cancers in the areas that cannot be 
accessed by the needle due to the random 
sampling of cancers that cannot be viewed 
using ultrasonography (US), and the second 
issue is the over-diagnosis of low grade cancer. 
In this sense, an important weakness has 
emerged in PCa imaging. With the increased 
clinical use of 3 Tesla (T) devices, PCa can be 
viewed with a high accuracy rate, which has led 
to the development of multiparametric prostate 
magnetic resonance imaging (mpMRI) [6, 7].  
An mpMRI is usually performed to identify 
localized cancers, along with elevated PSA. An 
mpMRI is aimed mainly at identifying 
clinically significant cancers (CSC: a tumor > 
0.5 cc, Gleason ≥3+4, extracapsular extension) 
[8], although some make use of mpMRI as the 
primary screening method [9]. 
The current guidelines differ in their 
recommendations on the use of mpMRI. The 
European Association of Urology (EAU) 
identifies two main strategies for mpMRI prior 
to biopsy: The first involves performing a 
systematic biopsy in all cases, regardless of the 
mpMRI result (positive or negative), and to add 
a targeted biopsy in the presence of a positive 
mpMRI; while second one involves only a 
targeted biopsy in the presence of a positive 
mpMRI, with no biopsy recommended in the 
event of a negative mpMRI. The EAU 
guidelines also point out that mpMRI is safer 
prior to a repeated biopsy [10].  
Additionally, mpMRI is recommended if there 
is any clinical suspicion of PCa prior to the 
biopsy, and that every lesion identified should 
be biopsied in a targeted and systematic way 
[10]. According to NCCN guidelines, mpMRI 
should be considered in the active follow-up 
group with a life expectancy of more than 10 
years in the very low- and low-risk groups. In 
cases where the biopsy is negative, yet a clinical 
suspicion still exists, mpMRI should be 
considered to allow observation of the anterior 
tumor in particular. mpMRI has also been 
recommended in the presence of elevated PSA 
in treated cases [5]. mpMRI has the same 
diagnostic power as computed tomography 
(CT) in identifying the pelvic pathological 
lymph node [11, 12]. mpMRI is also superior to 
bone scintigraphy and direct radiography in 
determining bone metastasis [13]. 
In the light of the above information, the 
present study assesses the accuracy of mpMRI 
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in the diagnosis and the determination of 
treatment options in PCa, and its pathology 
correlation. 
 
Materials and Methods 
A total of 73 patients underwent an mpMRI at 
our clinic between October 2017 and January 
2018, of which 11 were radical prostatectomy 
(RP) cases and four were post-RT follow-up 
cases.  
Patient exclusion criteria were standard MR 
contraindications and any previous prostate 
specific treatment (hormonal therapy, 
radiotherapy, or radical prostatectomy). Since 
no prostate imaging, reporting and data system 
(PI-RADS) categorization was made among the 
cases that had undergone treatment, so 15 cases 
were excluded from the study. The remaining 
58 patients were assigned to the PSA elevation 
and/or positive DRE patient group in the 
present study, and their outcomes were 
evaluated. PI-RADS assessments were made 
prospectively, and then the mpMRI results of 
the cases were compared with their pathology 
results. The study was conducted in accordance 
with the ethical approval of the University 
Ethics Committee (Number: 47104536-000-
8728). The rights of all participants were 
protected and written informed consents were 
obtained before the study according to the 
Helsinki Declaration. 
Transrectal ultrasonography-guided biopsies  
Biopsies were performed from 12 quadrants 
with a length of 15–22 mm by the guidance of 
a transrectal probe using a biopsy gun 
(Geotek® Estacore). 18 gauge needles were 
used. All patients were given antibiotic 
prophylaxis with ciprofloxacin before the 
procedure and bowel preparation was 
performed with an enema on the day of the 
procedure. The first dose was taken 1 day prior 
to biopsy and the second dose on the morning 
of the biopsy. The antibiotic prophylaxis was 
continued for 1–3 days after biopsy. Rectal 
swab culture or targeted antibiotic therapy was 
not performed as a standard prior to the 
biopsies.  
Multiparametric prostate magnetic resonance 
imaging (mpMRI)  
Multiparametric prostate MRI comprises three 
basic sequences to achieve anatomical and 
functional imaging [8]. The first sequence is 
T2-weighted (T2A) imaging with a high spatial 
resolution, which allows for the differentiation 
between structures, such as the transitional zone 
(TZ), peripheral zone (PZ), capsule, 
pseudocapsule and urethra, providing 
anatomical detail. The second basic sequence is 
diffusion-weighted imaging (DWI), which 
incorporates two different images: high b-
valued images (b=0, 200, 800 and 1400 
sec/mm2) and an apparent diffusion coefficient 
(ADC) map. DWI basically provides the image 
of the motion of water. Water moves freely in 
every direction in the extracellular space in 
normal prostate tissue, meaning that it displays 
an accelerated diffusion. In cases of increased 
cellularity and impaired tissue 
microarchitecture, the water cannot move 
freely in every direction, meaning that it 
displays a restricted diffusion. This manifests as 
a high signal on high b-value images and a low 
signal on the ADB map in DWI. The third basic 
sequence is dynamic contrast-enhanced (DCE) 
imaging, which provides details on tissue 
perfusion (in DCE, an at least 2-minute image 
is obtained in total every 15 seconds following 
the intravenous administration of a contrast 
agent. This allows information to be obtained 
on how fast the tissue gets blood, and how 
much, and how much of the blood it retains) 
[14].  
PI-RADS v2 scoring 
The scoring (categorization) was made based 
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on the recommended PI-RADS v.2 guidelines, 
which advise some dominant sequence scoring. 
Accordingly, peripheral zone (PZ) lesions are 
categorized based on the DWI score, while the 
transitional zone (TZ) lesions are based on the 
T2 score.  
Located in PZ, the linear or wedge lesions that 
are slightly low on ADC and isointense on high 
b-value image are categorized as score 2; those 
intermediately low on ADC and with a slightly 
high signal on high b-value image are 
categorized as score 3; those that are 
prominently low on ADC with a high signal on 
a high b-value image and <15 mm are 
categorized as score 4; those ≥15 mm with 
characteristics of a score 4 signal or lesions with 
an extraprostatic extension are categorized as 
score 5; and those with score 3 and early focal 
contrast involvement on DCE are categorized 
as score 3+1=4.  
Located in the TZ, lesions that are regular, 
encapsulated and nodular are categorized as 
score 2; those with heterogeneous signals and 
irregular contours are categorized as score 3; 
those that are homogeneous, hypointense and 
limited to the prostate and <15 mm are 
categorized as score 4; and those measuring 
≥15 mm with characteristics of a score 4 signal, 
or lesions with extraprostatic extensions, 
categorized as score 5 [8]. 
ISUP classification  
Today, pathology reports are required to include 
a grade classification, from 1 to 5, in addition to 
the Gleason score assignment for PCa [15]. 
Such classifications are made based on the 
guidelines for prostate cancer, which are graded 
in accordance with the scale identified at a 
consensus conference organized in 2014 by the 
International Society of Urological Pathology 
(ISUP). Upon the recommendations of the 2014 
consensus conference, the 2005 ISUP 
classification has been changed (Table 1).  
Table 1. The International Society of Urological 
Pathology (ISUP) grading system. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Statistical analysis 
Data analysis was performed with SPSS 
software, version 22 for Windows. Numerical 
parameters were expressed as mean ± standard 
deviation, minimum and maximum values, 
while categorical variables were expressed as 
frequency and percentage. The Mann-Whitney 
U test for nonparametric data was used to 
determine the significance of differences 
between the groups. P < 0.05 was considered to 
be statistically significant. 
 
Results  
Of the 58 patients included in the study, 13 were 
found to have a PI-RADS score of 5 on an 
mpMRI, 10 of which underwent concurrent 
biopsy and 9 (90%) were identified as having 
PCa ( One of them; Figure 1). Based on the 
biopsy results of the group with a PI-RADS 
score of 4, 71% were diagnosed with PCa, 
although 11 of the 20 patients evaluated as PI-
RADS 1 underwent a biopsy, and all were 
found to be benign (Table 2). 
ISUP 
grade 
Gleason 
scores    Definition 
Grade 1 2–6 Only individual discrete well-formed 
glands 
Grade 2 3+4=7 Predominantly well-formed glands 
with 
    lesser component of poorly 
formed/fused/ cribriform glands 
Grade 3 4+3=7 Predominantly poorly formed/fused/ 
    cribriform glands with lesser 
component of well-formed glands 
Grade 4 4+4=8 Only poorly formed/fused/cribriform 
glands 
  3+5=8 Predominantly well-formed glands and 
lesser component lacking glands  
(or with necrosis) 
      5+3=8 Predominantly lacking glands (or with 
    necrosis) and lesser component of 
    well-formed glands 
Grade 5 9–10 Lacking gland formation (or with 
necrosis) with or without poorly 
formed/fused/ cribriform glands 
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Figure 1. The left mid peripheral zone lesion 
(yellow arrows) was hypointense on T2WI (a), 
hyperintense on high b-value (b). It was vividly 
enhancing in early arterial dynamic imaging (c) 
and hypointense on ADC (d). This was a PI-
RADS category 5 lesion with a 31 mm 
diameter. It was diagnosed Gleason 4+3 after 
radical prostatectomy. 
 
 
 
 
 
 
 
 
 
 
All of the patients who were 3 and above 
according to the ISUP classification had a PI-
RADS category of 5 (Figures 2). Patients with 
a PI-RADS score of 4 and above being ISUP 2 
and above (CSC) was statistically significant 
(p=0.011).  
The additional case assessment revealed that 
tPSA increased to 2 ng/ml during the follow-up 
of one patient with a tPSA=9.94 ng/ml in 2014 
who was diagnosed with Gleason =3+4 upon 
the systematic biopsy, and who had undergone 
a previous radical prostatectomy, although the  
 
 
 
 
 
 
 
 
 
Figure 2. The PI-RADS distribution according 
to the ISUP classification (58 cases). 
 
surgical contour was negative and no metastasis 
was identified, and therefore RT was 
administered. An mpMRI performed upon the 
continued increase of tPSA during the follow-
up identified a 15x9 mm LAP in the left iliac 
region (Figure 3). During the follow-ups of the 
patient who had regional RT thereafter, the 
tPSA dropped below 0.01 ng/ml.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. 15x9-mm left main iliac LAP on 
contrasted T1A on mpMRI. 
Scoring Patients (n) 0 ISUP 1 ISUP 2 ISUP 3 ISUP 4 ISUP 5 Non-
Biopsy (n)  
PSA PSA D 
PIRADS 5 13 1 3 2 2 1 1 3 19 (4,6-124,91) 0,409 
PIRADS 4 10 2 3 2 0 0 0 3 6,79 (3,25-12,16) 0,159 
PIRADS 3+1 3 1 0 0 0 0 0 2 3,53 (1,99-5,23) 0,067 
PIRADS 3 4 0 1 1 0 0 0 2 4,55 (1,09-7,63) 0,098 
PIRADS 2 8 3 2 0 0 0 0 3 7,62 (2,12-18,74) 0,109 
PIRADS 1 20 11 0 0 0 0 0 9 5,69 (0,34-13,79) 0,072 
 
Table 2. The PI-RADS and ISUP results of 58 cases with PI-RADS scoring. 
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Discussion 
Prostate MRI was first used to evaluate 
extraprostatic invasion during PCa staging. 
Combining different sequences of MR imaging, 
mpMRI has gained in popularity in recent 
years, and has started to be used to guide TRUS 
biopsies for PCa diagnosis [16]. The 
significance of using mpMRI, especially prior 
to a prostate biopsy, was also emphasized in the 
2012 European Society of Uroradiology 
Guidelines [17]. 
In a review of the success of mpMRI, a study 
with 3T reported that CSC was detected in 99 
of 100 patients [18]. In another study, involving 
114 patients with no lesions identified on 
mpMRI, found identified no lesions in a 
systematic biopsy in 88 (77.2%) cases, while a 
Gleason 3+3 tumor and a Gleason 3+4 tumor 
was identified in 22 (19.3%) and 4 (3.6%) 
cases, respectively. The success in ruling out 
CSC was found to be 96.5%. All of the Gleason 
3+4 cases were observed to be patients with 
active follow-ups [19]. Another study also 
reported a very high rate of negative prediction 
for mpMRI (97–98.7%) [20].  
In light of the updated knowledge, a positive 
mpMRI (PI-RADS score of 4 or 5) allows a 
targeted biopsy to be performed in patients who 
have not undergone a biopsy, but who have an 
elevated PSA and/or positive DRE. With the 
negative mpMRI (PI-RADS score 1 or 2), the 
biopsy can be delayed and a PSA follow-up can 
be considered. A negative mpMRI has a very 
high success rate in ruling out CSC. A positive 
mpMRI can reveal anterior tumors or CSC in 
the region that cannot be accessed by a biopsy 
needle in patients with a negative biopsy 
history, despite an elevated PSA. A negative 
mpMRI, on the other hand, can reveal the 
causes of elevated PSA, such as prostatis, an 
enlarged prostate gland and BPH nodules. In 
patients with a positive biopsy history, a 
positive mpMRI can detect extracapsular 
extension, seminal vesicular invasion and 
neurovascular bundle invasion. This changes 
the treatment strategy (extended surgery or 
higher-dose radiotherapy rather than 
neuroprotective surgery). An active follow-up 
may be considered in the presence of a negative 
or minimal abnormal mpMRI, a low tumor 
volume, a Gleason 3+3 score or a short life 
expectancy (the NCC recommends monitoring 
only in the very low, low and intermediate risk 
groups, and with a life expectancy lower than 
10 years). However, mpMRI may not reveal 
high-risk cancer in some cases, and therefore 
careful PSA monitoring should be carried out 
during the active follow-up. In patients with a 
post-treatment elevated PSA, a positive 
mpMRI can display a recurrence, leading to 
early treatment. Again, these patients require 
close follow-up in the presence of a negative 
mpMRI, as in such cases, a systemic disease 
may be present [9]. 
In the present study, the identification of PCa in 
most of the cases with PI-RADS 4 or 5, and in 
groups of patients with pathologies of ISUP 2 
or more, allows for patient prediction prior to 
biopsy. Furthermore, it increased the rate CSC 
identification, and helped in the differentiation 
of a patient group that might require active 
follow-up. The benign biopsy result in all of the 
patients biopsied among the cases evaluated 
with PI-RADS 1 suggests that a biopsy may be 
avoided in patient groups recording such 
results. The study by Wang et al., which is in 
line with the present study, also reported 
reduced unnecessary diagnosis for the low-
grade cancer group, and avoided repeated 
biopsied through the performance of targeted 
biopsies [21]. 
mpMRI plays a significant role also in local 
assessment following prostate cancer treatment. 
An mpMRI following a radical prostatectomy, 
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RT and focal treatment may be used to visualize 
normal post-treatment changes and to detect 
recurrent diseases locally [22]. In the additional 
case assessment provided in our study, the tPSA 
of one patient who underwent a radical 
prostatectomy had increased, although the 
surgical contour was negative and no metastasis 
was identified during follow-ups, and the 
patient received RT. However, an mpMRI 
performed after a continued increase of tPSA 
was identified during follow-up revealed a LAP 
in the left iliac region. A regional RT was 
administered and tPSA dropped below 0.01 
ng/ml during the follow-up, which supports its 
usefulness in viewing recurrences. 
This study has some limitations. Firstly, it is 
retrospectively designed. Secondly, our sample 
number is a little low, but it is acceptable for a 
pilot study.  Also, the mpMRI has started to be 
applied in the near future. 
It can be understood from the findings of the 
present study that mpMRI has gained a novel 
and significant place in urology in providing 
guidance to biopsies, in allowing targeted 
biopsies to be performed, in aiding in the 
determination of treatment modalities and in its 
significant contributions to post-PCa treatment 
follow-ups. That said, the number of 
participants in our study needs to be increased 
in order to reflect the general population, and so 
further studies are required.  
 
Conclusion 
MpMRI has gained a novel and significant 
place in urology in providing guidance to 
biopsies, in allowing targeted biopsies to be 
performed, in aiding in the determination of 
treatment modalities and in its significant 
contributions to post-PCa treatment follow-ups. 
Additionally, mpMRI can also be considered an 
appropriate imaging method for revealing 
localized tumors in cases with recurrent PSA. 
Our study observed that a targeted biopsy is 
required at the diagnostic stage, and the PI-
RADS classification is an important indicator 
of biopsy. 
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